EGFR和VEGF在三阴乳腺癌中的表达及意义(3)
 |
| 第1页 |
参见附件。
参考文献
[1] Corkery B,Crown J,Clynes M,et al.Epidemal growth factor receptor as a potential therapeutic target in triple neggative breast cancer[J].Ann Oncol,2009,20(7):862-867.
[2] Shivakumar S,Prabhakar B T,Jayashree K,et al.Evaluation of serum vascular emdothelial growth factor(VEGF) and microvessel density(MVD) as prognostic indicators in carcinoma breast[J].Cancer Res Clin Oncol,2009, 135 (4): 627-636.
[3] Wells A.The epidermal growth factor receptor(EGFR):A new target in cancer therapy[J]. Singal,2000,1(1):4.
[4] Nielsen T O,Hsu F D,Jensen K,et al.Immunohistochemical and clinica characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367-5374.
[5] Czyzewska J,Guzinsha-Ustumowicz M.The expression of E-cadhein-catenin complex in patients with advanced gastric cancer:role in formation of metastasis[J].Folia Histochem Cytobiol,2010,48(1):37-45.
[6] Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective[J]. Clin Cancer Res, 2006, 12 (17):5018-5022.
[7] Linderholm B K, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer[J]. Ann Oncol, 2009, 20(10): 1639-1646.
[8] Nishimura R, Nagao K, Miyayama H, et al. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer[J]. Breast Cancer,2003, 10 (2): 120-128.
[9] Ryden L, Jirstrom K, Haglund M, et al. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer.Results from a controlled randomized trial with long-term follow-up[J].Breast Cancer Res Treat, 2010, 120(2): 491-498.
(收稿日期:2012-08-16) (本文编辑:车艳)
您现在查看是摘要介绍页，详见PDF附件(2635kb)。